IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward Approximately 30% of patients with early breast cancer (EBC) will eventually develop metastatic disease. In hormone receptor (HR)-positive breast cancer, approximately 50% of recurrences occurs within 5 years of diagnosis. Many factors should be considered when

https://www.medscape.org/advances/implementing-advances-cancer-treatment-patients-hr-her2-2025a1000yzz?src=mkmcmr_driv_32025_mscpedu_436313.01_ace_final&uac=148436CN